Download PDF
Aktuelle Neurologie 2014; 41(03): 173-177
DOI: 10.1055/s-0034-1369895
Debatte: Pro & Kontra
© Georg Thieme Verlag KG Stuttgart · New York

Intravenöse Immunglobuline sind die Therapie der ersten Wahl bei der CIDP

Intravenous Immunoglobulines are First Line Therapy for the Treatment of Chronic Inflammatory Demyelinating Polyneuroradiculopathy
S. Wenninger
Friedrich-Baur-Institut, Neurologische Klinik, Interdisziplinäres Zentrum für Neuromuskuläre Erkrankungen des Klinikums der Universität München
,
B. Schoser
Friedrich-Baur-Institut, Neurologische Klinik, Interdisziplinäres Zentrum für Neuromuskuläre Erkrankungen des Klinikums der Universität München
› Author Affiliations
Further Information

Publication History

Publication Date:
21 March 2014 (online)

Also available at
    Permissions and Reprints

Pro

Entscheidende Grundlage einer erfolgreichen Therapie der chronisch inflammatorischen demyelinisierenden Polyradikuloneuropathie (CIDP) ist die korrekte Diagnose. Zur medikamentösen Behandlung der CIDP werden effektiv, d. h. symptomverbessernd, seit den 1950er-Jahren Glukokortikoide (Evidenzklasse Ib) eingesetzt. Seit den 1980er-Jahren stehen zudem i. v. Immunglobuline (IVIg) zur Verfügung.

 

  • Literatur

  • 1 van Doorn PA, Merkies IS. How to assess new drugs for neuropathies: advances in trial design and methodology. Curr Opin Neurol 2008; 21: 519-526
    CrossrefPubMedGoogle Scholar
  • 2 Hughes RA, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332
    CrossrefPubMedGoogle Scholar
  • 3 Cocito D, Paolasso I, Antonini G et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294
    CrossrefPubMedGoogle Scholar
  • 4 Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144
    CrossrefPubMedGoogle Scholar
  • 5 Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201
    CrossrefPubMedGoogle Scholar
  • 6 Ropper AH. Current treatments for CIDP. Neurology 2003; 60: 16-22
    CrossrefPubMedGoogle Scholar
  • 7 Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11: 493-502
    CrossrefPubMedGoogle Scholar
  • 8 Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci 2013; 34: 445-457
    CrossrefPubMedGoogle Scholar
  • 9 Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. Journal of neuroimmunology 2011; 231: 61-69
    CrossrefPubMedGoogle Scholar
  • 10 Rosen FS. Putative mechanisms of the effect of intravenous gamma-globulin. Clin Immunol Immunopathol 1993; 67: 41-43
    CrossrefPubMedGoogle Scholar
  • 11 Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. The Journal of clinical investigation 1994; 94: 1729-1735
    CrossrefPubMedGoogle Scholar
  • 12 Hartung HP. Advances in the understanding of the mechanism of action of IVIg. Journal of neurology 2008; 255 (Suppl. 03) 3-6
    PubMedGoogle Scholar
  • 13 Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 2003; 135: 91-95
    CrossrefPubMedGoogle Scholar
  • 14 Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792
    CrossrefPubMedGoogle Scholar
  • 15 Bick S, Tschernatsch M, Karg A et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy – a new mechanism of action?. J Neuroimmunol 2013; 256: 84-90
    CrossrefPubMedGoogle Scholar
  • 16 Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-545
    CrossrefPubMedGoogle Scholar
  • 17 Lin CS, Krishnan AV, Park SB et al. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68: 862-869
    CrossrefPubMedGoogle Scholar
  • 18 Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412
    CrossrefPubMedGoogle Scholar
  • 19 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord 2012; 5: 359-373
    CrossrefPubMedGoogle Scholar
  • 20 Latov N, Deng C, Dalakas MC et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurology 2010; 67: 802-807
    CrossrefPubMedGoogle Scholar
  • 21 Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2009; CD001797
    PubMedGoogle Scholar
  • 22 Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database of systematic reviews 2012; (08) CD002062
    PubMedGoogle Scholar
  • 23 Merkies IS, van Nes SI, Hanna K et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 2010; 81: 1194-1199
    CrossrefPubMedGoogle Scholar
  • 24 Donofrio PD, Bril V, Dalakas MC et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082-1088
    CrossrefPubMedGoogle Scholar
  • 25 Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic advances in neurological disorders 2012; 5: 359-373
    CrossrefPubMedGoogle Scholar
  • 26 Hughes R. The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol 2008; 255 (Suppl. 03) 7-11
    PubMedGoogle Scholar
  • 27 Blackhouse G, Gaebel K, Xie F et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8: 14
    CrossrefPubMedGoogle Scholar
  • 28 Bae SC, Corzillius M, Kuntz KM et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 46-53
    CrossrefPubMedGoogle Scholar